Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
CNSCohen & Steers(CNS) Seeking Alpha·2024-10-10 19:42

I'm a biotech and healthcare investment analyst with several years of clinical experience and a Master of Business Administration. I've had the privilege of sharing my analyses on Seeking Alpha since 2017. Outside of spending time with family, this is my favorite thing to do. I utilize risk-return charts and DCF analyses to highlight investment opportunities and risks. I'm a big fan of the barbell strategy: 90% in safe assets like Treasuries and ETFs, and 10% in high-growth stocks—keeping risk management fr ...